A Phase 3 interventional study of Sitagliptin and Comparator: Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-08-17.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 19th largest by enrollment of the 197 interventional ones that give a count, is one of 16 that started in 2012, is one of 74 in phase 3, and was the 107th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 16 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 660 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 25th largest by enrollment of the 170 interventional ones that give a count, is one of 20 that started in 2012, is one of 86 in phase 3, and was the 121st registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the insulin-sparing effect of sitagliptin 100 mg once-daily compared with placebo over 24 weeks in participants with type 2 diabetes mellitus who have inadequate glycemic control on insulin alone or in combination with metformin. The primary hypothesis of this study is that after 24 weeks, sitagliptin reduces the dose of insulin relative to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
has one of the following criteria:
Exclusion Criteria:
pre-prandial short-acting or rapid-acting insulin alone or as part of a basal/bolus insulin regimen
coma, or loss of consciousness, - or - has had recurrent (≥3 times per week) episodes of hypoglycemia over the past 8 weeks
therapy and has not been on a stable dose for at least 6 weeks
steatosis)
congestive heart failure within the past 3 months, or has any of the following
disorders within the past 3 months:
stroke or transient ischemic neurological disorder
during the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sitagliptin 100 mg once daily
Drug: Sitagliptin · Biological: Insulin Glargine · Drug: Metformin
Placebo to sitagliptin once daily
Drug: Comparator: Placebo · Biological: Insulin Glargine · Drug: Metformin
Sitagliptin 100 mg tablet once daily for 24 weeks
Also known as: Januvia
Placebo to sitagliptin once daily for 24 weeks
Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.
Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.
Also known as: Glucophage
Change From Baseline in Daily Insulin Dose at Week 24
Change in daily insulin dose following 24 weeks of therapy (i.e., daily insulin dose at Week 24 minus daily insulin dose at baseline)
Time frame: Baseline and Week 24
Change From Baseline in Hemoglobin A1c (A1C) at Week 24
A1C is measured as the percentage of glycosylated hemoglobin. Change in A1C following 24 weeks of therapy (i.e., A1C at Week 24 minus A1C at baseline)
Time frame: Baseline and Week 24
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
Change in FPG (before breakfast) following 24 weeks of therapy (i.e., FPG at Week 24 minus FPG at baseline)
Time frame: Baseline and Week 24
Percent of Participants Achieving Fasting Glucose Target at Any Time During the Study
The fasting glucose target was defined as 3 consecutive days with a fingerstick glucose of 72 to 100 mg/dL (4.0 - 5.6 mmol/L).
Time frame: Up to 24 weeks
Time to Achieve the Fasting Glucose Target
Fasting glucose target 3 consecutive days with a fingerstick glucose of 72 to 100 mg/dL (4.0 - 5.6 mmol/L). This analysis was the Kaplan-Meier estimated 50th percentile of time (days) to first attainment of target.
Time frame: Up to 24 weeks
| Milestone | Sitagliptin | Placebo |
|---|---|---|
| Started | 330 | 330 |
| Treated | 329 | 329 |
| Completed | 295 | 303 |
| Not completed | 35 | 27 |
| Withdrew: Adverse event | 7 | 6 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Non-compliance with study drug | 3 | 0 |
| Withdrew: Creatinine and egfr, excluded medication | 8 | 4 |
| Withdrew: Physician decision | 2 | 5 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Withdrawal by subject | 7 | 2 |
| Withdrew: Screen failure | 1 | 1 |
Change in daily insulin dose following 24 weeks of therapy (i.e., daily insulin dose at Week 24 minus daily insulin dose at baseline)
| International Units (IU) | Sitagliptin | Placebo |
|---|---|---|
| Change From Baseline in Daily Insulin Dose at Week 24 | 19.0 ± 19.6 | 23.8 ± 24.0 |
A1C is measured as the percentage of glycosylated hemoglobin. Change in A1C following 24 weeks of therapy (i.e., A1C at Week 24 minus A1C at baseline)
| Percent of total hemoglobin | Sitagliptin | Placebo |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (A1C) at Week 24 | -1.31 ± 0.98 | -0.87 ± 1.10 |
Change in FPG (before breakfast) following 24 weeks of therapy (i.e., FPG at Week 24 minus FPG at baseline)
| mg/dL | Sitagliptin | Placebo |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 | -55.5 ± 52.0 | -44.8 ± 62.4 |
The fasting glucose target was defined as 3 consecutive days with a fingerstick glucose of 72 to 100 mg/dL (4.0 - 5.6 mmol/L).
| Percentage of participants | Sitagliptin | Placebo |
|---|---|---|
| Percent of Participants Achieving Fasting Glucose Target at Any Time During the Study | 77.4 (72.6 to 82.2) | 74.1 (69.0 to 79.2) |
Fasting glucose target 3 consecutive days with a fingerstick glucose of 72 to 100 mg/dL (4.0 - 5.6 mmol/L). This analysis was the Kaplan-Meier estimated 50th percentile of time (days) to first attainment of target.
| Days to first attainment of target | Sitagliptin | Placebo |
|---|---|---|
| Time to Achieve the Fasting Glucose Target | 78 (64 to 85) | 90 (80 to 107) |
Collected over Up to Week 24 + 14-day follow-up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin | — | 13/329 (4%) | 121/329 (36.8%) |
| Placebo | — | 12/329 (3.6%) | 168/329 (51.1%) |
| Event | Sitagliptin | Placebo |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/329 | 1/329 |
| Acute coronary syndromeCardiac disorders | 0/329 | 1/329 |
| Acute myocardial infarctionCardiac disorders | 0/329 | 1/329 |
| Angina pectorisCardiac disorders | 0/329 | 1/329 |
| Coronary artery diseaseCardiac disorders | 1/329 | 0/329 |
| Myocardial infarctionCardiac disorders | 1/329 | 1/329 |
| Chest painGeneral disorders | 1/329 | 0/329 |
| HypersensitivityImmune system disorders | 0/329 | 1/329 |
| Appendicitis perforatedInfections and infestations | 1/329 | 0/329 |
| CellulitisInfections and infestations | 1/329 | 1/329 |
| Event | Sitagliptin | Placebo |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 93/329 | 144/329 |
| NasopharyngitisInfections and infestations | 13/329 | 26/329 |
| DiarrhoeaGastrointestinal disorders | 17/329 | 11/329 |
| Urinary tract infectionInfections and infestations | 14/329 | 17/329 |
One participant in both the Sitagliptin group and Placebo group was randomized in error and did not receive study medication.
| Age, Continuous(Years) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Mean | 59.3 ± 8.9 | 58.3 ± 9.7 | 58.8 ± 9.3 |
| Sex: Female, Male(Participants) | Sitagliptin | Placebo | Total |
|---|---|---|---|
| Female | 178 | 165 | 343 |
| Male | 151 | 164 | 315 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jan 2012 to primary completion in Jun 2013, 16 months.
Results were first posted in Apr 2014, 10 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin